Sugi Predict

Sugi Predict / Compounds / SCHEMBL343267

SCHEMBL343267

SCHEMBL343267

CC(C)(C)OC(=O)C(Br)CCBr

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ZDHHC7 Q9NXF8 1/20 0.36
▸ NOS1 P29475 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ NOS3 P29474 1/20 0.33
▸ NOS2 P35228 1/20 0.33
▸ AAK1 Q2M2I8 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ DGAT1 O75907 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8785206 0.89 ZDHHC7 (0.39) ZDHHC7NOS1KMT2AMEN1GAA
SCHEMBL6474533 0.88 ZDHHC7 (0.42) ZDHHC7NOS1KMT2AMEN1GAA
SCHEMBL7894283 0.86 ZDHHC7 (0.44) ZDHHC7NOS1KMT2AMEN1GAA
SCHEMBL9691868 0.83 ZDHHC7 (0.44) ZDHHC7NOS1KMT2AMEN1GAA
SCHEMBL6337940 0.83 ALDH1A1 (0.42) ZDHHC7NOS1KMT2AMEN1GAA
SCHEMBL1286840 0.82 NOS1 (0.36) ZDHHC7NOS1KMT2AMEN1GAA
SCHEMBL6305191 0.81 KMT2A (0.34) NOS1KMT2AMEN1GAANOS3
SCHEMBL26100054 0.81 KMT2A (0.38) NOS1KMT2AMEN1GAANOS3
SCHEMBL9352351 0.80 KMT2A (0.33) ZDHHC7NOS1KMT2AMEN1GAA
SCHEMBL23552907 0.80 HDAC3 (0.35) ZDHHC7NOS1KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2026-05-14 — — US disclosed
US-12595245-B2 Inhibitors of MET kinase CELYN THERAPEUTICS, INC. (US) 2026-04-07 — — US disclosed
US-12509470-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2025-12-30 — — US disclosed
WO-2025217247-A1 TETHERED SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2025-10-16 — — WO disclosed
EP-4598917-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF Amgen Inc. (US) 2025-08-13 — — EP disclosed
US-20250084044-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2025-03-13 — — US disclosed
EP-4462999-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS Enko Chem, Inc. (US) 2024-11-20 — — EP disclosed
EP-4448510-A1 INHIBITORS OF MET KINASE Kinnate Biopharma Inc. (US) 2024-10-23 — — EP disclosed
CN-118742542-A Inhibitors of MET kinase 金耐特生物制药公司 2024-10-01 — — CN disclosed
CN-118541030-A Protoporphyrinogen oxidase inhibitors 恩科化学公司 2024-08-23 — — CN disclosed
US-20040059109-A1 Alanine 2, 6-dialkoxyphenyl ester derivatives as hypnotics N.V. ORGANON (NL) 2004-03-25 — — US disclosed
EP-1373188-A1 ALANINE 2,6-DIALKOXYPHENYL ESTER DERIVATIVES AS HYPNOTICS Akzo Nobel N.V. (NL) 2004-01-02 — — EP disclosed
WO-2002057218-A1 ALANINE 2,6-DIALKOXYPHENYL ESTER DERIVATIVES AS HYPNOTICS AKZO NOBEL N.V. (NL) 2002-07-25 — — WO disclosed
CN-1308614-A Benzimidazoles, production thereof and use thereof medicaments BOEHRINGER INGELHEIM PHAMA KG (DE) 2001-08-15 — — CN disclosed
US-6248770-B1 CARDIOVASCULAR DISORDERS BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-06-19 — — US disclosed
EP-1083918-A1 NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS Advanced Medicine, Inc. (US) 2001-03-21 — — EP disclosed
US-6180611-B1 INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR DARWIN DISCOVERY, LTD. (GB) 2001-01-30 — — US disclosed
WO-1999064044-A1 NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS ADVANCED MEDICINE, INC. (US) 1999-12-16 — — WO disclosed
US-5994312-A Peptidyl compounds DARWIN DISCOVERY, LTD. (GB) 1999-11-30 — — US disclosed
CN-1228772-A Heterocyclic metalloprotease inhibitors PROCTER & GAMBLE (US) 1999-09-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084044-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS PPOX, CYP4X1, PNPO ZDHHC7 2447/4885NOS1 2533/4885KMT2A 4160/4885
US-12595245-B2 Inhibitors of MET kinase MET, ABL1, ERBB2 ZDHHC7 2975/4885NOS1 2650/4885KMT2A 422/4885
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF KRAS, NRAS, HRAS ZDHHC7 626/4885NOS1 4837/4885KMT2A 3439/4885
US-12509470-B2 Antiviral heterocyclic compounds NR3C1, ZC3HAV1, HAVCR2 ZDHHC7 2207/4885NOS1 1778/4885KMT2A 2895/4885
US-20040059109-A1 Alanine 2, 6-dialkoxyphenyl ester derivatives as hypnotics OPRM1, OPRD1, OPRK1 ZDHHC7 2476/4885NOS1 920/4885KMT2A 2031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.